Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Neuroscience, and Director of the Center for Neurovirology and the Comprehensive NeuroAIDS Center at the Lewis Katz School of Medicine at Temple University (LKSOM), will lead a project at LKSOM evaluating the medication Piclidenoson and its effect on the viral load of coronaviruses in a mammalian cell model system. Piclidenoson is currently undergoing a Phase III clinical trial to treat rheumatoid arthritis. It has previously demonstrated anti-viral activity against HIV, which is a single-stranded RNA virus – as are coronaviruses. Pharmaceutical Technology covered the news.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH
Related News
Major Advances in Treating Lung Blood Clots Could Eliminate Need for ICU Stay, According to New Research at the Lewis Katz School of Medicine at Temple University
Posted November 22, 2024A novel “on-the-table” therapeutic strategy with a total procedure time of less than one hour can safely reduce the size of blood clots lodged in the pulmonary arteries and eliminate the need for post-procedural drug infusion in an intensive care unit, according to Katz School of Medicine research.
Read MoreHealio Highlights Dr. Kristin Criner’s Session at the GOLD International COPD Conference
Posted November 21, 2024Healio highlighted the key takeaways from Dr. Criner’s session on how to identify and treat patients with COPD plus diabetes or osteoporosis.
Read More